Literature DB >> 23725921

Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum.

Andrzej Rynkiewicz1, Barbara Cybulska, Maciej Banach, Krzysztof Filipiak, Tomasz Guzik, Barbara Idzior-Waluś, Jacek Imiela, Piotr Jankowski, Longina Kłosiewicz-Latoszek, Janusz Limon, Małgorzata Myśliwiec, Grzegorz Opolski, Andrzej Steciwko, Janina Stępińska, Tomasz Zdrojewski.   

Abstract

Heterozygous familial hypercholesterolemia (HFH) affects on average 1 in 500 individuals in European countries, and it is estimated that HeFH in Poland may affect more than 80,000 people. Cardiovascular mortality in individuals with FH between 20 and 39 years of age is 100 times higher than in the general population. HFH is a relatively common lipid disorder, but usually still remaining undiagnosed and untreated. A very high risk of cardiovascular diseases and a shortened lifespan in patients with this condition require early diagnosis and intensive treatment. The aim of the position paper was to present the importance and scale of this problem in Poland, which has not been raised enough so far, as well as the recommendations of diagnosis, treatment and prevention methods.
Copyright © 2013 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23725921     DOI: 10.1016/j.jacl.2013.01.005

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  12 in total

1.  PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.

Authors:  Maciej Banach; Piotr Jankowski; Jacek Jóźwiak; Barbara Cybulska; Adam Windak; Tomasz Guzik; Artur Mamcarz; Marlena Broncel; Tomasz Tomasik; Jacek Rysz; Agnieszka Jankowska-Zduńczyk; Piotr Hoffman; Agnieszka Mastalerz-Migas
Journal:  Arch Med Sci       Date:  2016-12-19       Impact factor: 3.318

Review 2.  The panorama of familial hypercholesterolemia in Latin America: a systematic review.

Authors:  Roopa Mehta; Rafael Zubirán; Alexandro J Martagón; Alejandra Vazquez-Cárdenas; Yayoi Segura-Kato; María Teresa Tusié-Luna; Carlos A Aguilar-Salinas
Journal:  J Lipid Res       Date:  2016-10-24       Impact factor: 5.922

3.  PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.

Authors:  Maciej Banach; Paweł Burchardt; Krzysztof Chlebus; Piotr Dobrowolski; Dariusz Dudek; Krzysztof Dyrbuś; Mariusz Gąsior; Piotr Jankowski; Jacek Jóźwiak; Longina Kłosiewicz-Latoszek; Irina Kowalska; Maciej Małecki; Aleksander Prejbisz; Michał Rakowski; Jacek Rysz; Bogdan Solnica; Dariusz Sitkiewicz; Grażyna Sygitowicz; Grażyna Sypniewska; Tomasz Tomasik; Adam Windak; Dorota Zozulińska-Ziółkiewicz; Barbara Cybulska
Journal:  Arch Med Sci       Date:  2021-11-08       Impact factor: 3.318

4.  The genetic spectrum of familial hypercholesterolemia in south-eastern Poland.

Authors:  Mahtab Sharifi; Małgorzata Walus-Miarka; Barbara Idzior-Waluś; Maciej T Malecki; Marek Sanak; Ros Whittall; Ka Wah Li; Marta Futema; Steve E Humphries
Journal:  Metabolism       Date:  2015-11-10       Impact factor: 8.694

5.  LDL apheresis in a woman with severe heterozygous familial hypercholesterolemia. Late, but not too late.

Authors:  Agnieszka Mickiewicz; Marcin Fijałkowski; Andrzej Rynkiewicz; Grzegorz Raczak; Marcin Gruchała
Journal:  Arch Med Sci       Date:  2015-12-11       Impact factor: 3.318

Review 6.  Prevalence of familial hypercholesterolemia: a meta-analysis of six large, observational, population-based studies in Poland.

Authors:  Andrzej Pajak; Krystyna Szafraniec; Maciej Polak; Wojciech Drygas; Walerian Piotrowski; Tomasz Zdrojewski; Piotr Jankowski
Journal:  Arch Med Sci       Date:  2016-05-05       Impact factor: 3.318

7.  2D-STI combined with gated 99Tcm-MIBI MPI for the diagnosis of myocardial ischemia in hypercholesterolemia patients.

Authors:  Yi Song; Rui-Fang Zhang; Yu Liu
Journal:  Exp Ther Med       Date:  2017-06-14       Impact factor: 2.447

8.  Clinical management of heterozygous familial hypercholesterolemia in a Polish outpatient metabolic clinic: a retrospective observational study.

Authors:  Longina Kłosiewicz-Latoszek; Barbara Cybulska; Janina Białobrzeska-Paluszkiewicz; Anna Jagielska; Jolanta Janowska; Dorota Danowska; Anna Reguła; Małgorzata Stroniawska-Woźniak
Journal:  Arch Med Sci       Date:  2017-11-30       Impact factor: 3.318

9.  Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate.

Authors:  Arrigo F G Cicero; Giuseppe Derosa; Pamela Maffioli; Alessandra Reggi; Elisa Grandi; Claudio Borghi
Journal:  Arch Med Sci       Date:  2013-04-09       Impact factor: 3.318

10.  PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.

Authors:  Krzysztof Jaworski; Piotr Jankowski; Dariusz A Kosior
Journal:  Arch Med Sci       Date:  2017-01-19       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.